Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

Innovent Announces First Patient With Type 2 Diabetes Dosed In A Phase 2 Clinical Trial Of Ibi362 (a Glp 1r And Glucagon Receptor Dual Agonist) In China

Facebook Comments

Leave a Reply

CommentLuv badge